About the Company

Abivax SA (Euronext Paris: ABVX.PA) is developing novel therapies to treat serious infectious diseases. The Company’s lead product candidate, ABX203, is a therapeutic vaccine to treat hepatitis B. Abivax has completed enrollment for a Phase II/III trial evaluating ABX203 and expects to report topline data in the fourth quarter of 2016. Abivax is also evaluating ABX464 as a potential treatment for HIV. Phase IIa data for this program was recently presented showing a dose-dependent reduction in viral load with no indications of drug resistance. The Company plans to conduct a second Phase IIa trial with ABX464 to test the durability of the drug’s effect.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research